27494903|t|Identification of novel macrolides with antibacterial, anti-inflammatory and type I and III IFN - augmenting activity in airway epithelium
27494903|a|Exacerbations of asthma and COPD are triggered by rhinoviruses. Uncontrolled inflammatory pathways, pathogenic bacterial burden and impaired antiviral immunity are thought to be important factors in disease severity and duration. Macrolides including azithromycin are often used to treat the above diseases, but exhibit variable levels of efficacy. Inhaled corticosteroids are also readily used in treatment, but may lack specificity. Ideally, new treatment alternatives should suppress unwanted inflammation, but spare beneficial antiviral immunity. In the present study, we screened 225 novel macrolides and tested them for enhanced antiviral activity against rhinovirus, as well as anti-inflammatory activity and activity against Gram-positive and Gram-negative bacteria. Primary bronchial epithelial cells were grown from 10 asthmatic individuals and the effects of macrolides on rhinovirus replication were also examined. Another 30 structurally similar macrolides were also examined. The oleandomycin derivative Mac5, compared with azithromycin, showed superior induction (up to 5-fold, EC 50 = 5-11 μM) of rhinovirus - induced type I IFNβ, type III IFNλ1 and type III IFNλ2/3 mRNA and the IFN - stimulated genes viperin and MxA, yet had no effect on IL-6 and IL-8 mRNA. Mac5 also suppressed rhinovirus replication at 48 h, proving antiviral activity. Mac5 showed antibacterial activity against Gram-positive Streptococcus pneumoniae; however, it did not have any antibacterial properties compared with azithromycin when used against Gram-negative Escherichia coli (as a model organism) and also the respiratory pathogens Pseudomonas aeruginosa and non-typeable Haemophilus influenzae. Further non-toxic Mac5 derivatives were identified with various anti-inflammatory, antiviral and antibacterial activities. The data support the idea that macrolides have antiviral properties through a mechanism that is yet to be ascertained. We also provide evidence that macrolides can be developed with anti-inflammatory, antibacterial and antiviral activity and show surprising versatility depending on the clinical need.
27494903	24	34	macrolides	T103	UMLS:C0282563
27494903	40	53	antibacterial	T038	UMLS:C0544570
27494903	77	83	type I	T103	UMLS:C0021747
27494903	88	95	III IFN	T103	UMLS:C0021747
27494903	98	117	augmenting activity	T033	UMLS:C0243095
27494903	121	127	airway	T017	UMLS:C0458827
27494903	128	138	epithelium	T017	UMLS:C0014609
27494903	139	162	Exacerbations of asthma	T033	UMLS:C0349790
27494903	167	171	COPD	T038	UMLS:C0740304
27494903	189	201	rhinoviruses	T005	UMLS:C0035473
27494903	216	237	inflammatory pathways	T038	UMLS:C1512758
27494903	280	298	antiviral immunity	T038	UMLS:C1155328
27494903	369	379	Macrolides	T103	UMLS:C0282563
27494903	390	402	azithromycin	T103	UMLS:C0052796
27494903	437	445	diseases	T038	UMLS:C0012634
27494903	635	647	inflammation	T038	UMLS:C0021368
27494903	670	688	antiviral immunity	T038	UMLS:C1155328
27494903	705	710	study	T058	UMLS:C0947630
27494903	734	744	macrolides	T103	UMLS:C0282563
27494903	774	792	antiviral activity	T038	UMLS:C1321382
27494903	801	811	rhinovirus	T005	UMLS:C0035473
27494903	824	850	anti-inflammatory activity	T033	UMLS:C0243095
27494903	872	885	Gram-positive	T007	UMLS:C0018154
27494903	890	912	Gram-negative bacteria	T007	UMLS:C0018150
27494903	922	948	bronchial epithelial cells	T017	UMLS:C1711178
27494903	1009	1019	macrolides	T103	UMLS:C0282563
27494903	1023	1033	rhinovirus	T005	UMLS:C0035473
27494903	1034	1045	replication	T038	UMLS:C0042774
27494903	1056	1064	examined	T033	UMLS:C0332128
27494903	1098	1108	macrolides	T103	UMLS:C0282563
27494903	1119	1127	examined	T033	UMLS:C0332128
27494903	1133	1145	oleandomycin	T103	UMLS:C0028923
27494903	1157	1161	Mac5	T103	UMLS:C0028923
27494903	1177	1189	azithromycin	T103	UMLS:C0052796
27494903	1252	1262	rhinovirus	T005	UMLS:C0035473
27494903	1273	1284	type I IFNβ	T017	UMLS:C1334081
27494903	1286	1300	type III IFNλ1	T017	UMLS:C1334085
27494903	1305	1321	type III IFNλ2/3	T017	UMLS:C1334085
27494903	1322	1326	mRNA	T103	UMLS:C0035696
27494903	1335	1338	IFN	T103	UMLS:C0021747
27494903	1352	1357	genes	T017	UMLS:C0017337
27494903	1358	1365	viperin	T017	UMLS:C1539703
27494903	1370	1373	MxA	T017	UMLS:C1417510
27494903	1396	1400	IL-6	T017	UMLS:C1334122
27494903	1405	1409	IL-8	T017	UMLS:C1366571
27494903	1410	1414	mRNA	T103	UMLS:C0035696
27494903	1416	1420	Mac5	T103	UMLS:C0028923
27494903	1437	1447	rhinovirus	T005	UMLS:C0035473
27494903	1448	1459	replication	T038	UMLS:C0042774
27494903	1477	1495	antiviral activity	T038	UMLS:C1321382
27494903	1497	1501	Mac5	T103	UMLS:C0028923
27494903	1509	1531	antibacterial activity	T038	UMLS:C0544570
27494903	1540	1553	Gram-positive	T007	UMLS:C0018154
27494903	1554	1578	Streptococcus pneumoniae	T007	UMLS:C0038410
27494903	1609	1633	antibacterial properties	T038	UMLS:C0544570
27494903	1648	1660	azithromycin	T103	UMLS:C0052796
27494903	1679	1692	Gram-negative	T007	UMLS:C0018150
27494903	1693	1709	Escherichia coli	T007	UMLS:C0014834
27494903	1767	1789	Pseudomonas aeruginosa	T007	UMLS:C0033809
27494903	1807	1829	Haemophilus influenzae	T007	UMLS:C0018483
27494903	1849	1853	Mac5	T103	UMLS:C0028923
27494903	1914	1923	antiviral	T038	UMLS:C1321382
27494903	1928	1952	antibacterial activities	T038	UMLS:C0544570
27494903	1985	1995	macrolides	T103	UMLS:C0282563
27494903	2001	2021	antiviral properties	T038	UMLS:C1321382
27494903	2103	2113	macrolides	T103	UMLS:C0282563
27494903	2155	2168	antibacterial	T038	UMLS:C0544570
27494903	2173	2191	antiviral activity	T038	UMLS:C1321382